Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology

M H A Jansen, D G van Vuurden, W P Vandertop, G J L Kaspers

Research output: Contribution to journalReview articlepeer-review

177 Citations (Scopus)


Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalCancer treatment reviews
Issue number1
Publication statusPublished - Feb 2012
Externally publishedYes


  • Animals
  • Antineoplastic Agents/therapeutic use
  • Brain Stem Neoplasms/drug therapy
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Humans
  • Molecular Targeted Therapy
  • Pons/pathology
  • Treatment Outcome


Dive into the research topics of 'Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology'. Together they form a unique fingerprint.

Cite this